HOME >> BIOLOGY >> NEWS
Other highlights in the September 7 JNCI

ding ER activity in PR-negative breast cancer. "These data could have a profound translational clinical impact on directing therapeutic interventions for patients who have ER-positive tumors but who display a steroid hormoneresistant or independent phenotype," they write.

Contact:

  • Article: Kimberlee Barbour, Baylor College of Medicine, 713-798-4712, kbarbour@bcm.edu
  • Editorial: Kim Irwin, University of California Los Angeles, 310-206-2805, kirwin@mednet.ucla.edu

    Hirschsprung Disease Gene May Also Be Involved in Some Melanomas

    A new study has found that mutations in a gene involved in Hirschsprung disease--a rare disease of the colon that usually occurs in children--may also predispose carriers to malignant melanoma.

    Because the endothelin signaling pathway plays an important role in the differentiation and migration of melanocytes, the cells from which melanomas arise, Nadem Soufir, M.D., Ph.D., of the Hopital Bichat-Claude Bernard in Paris, and colleagues investigated whether mutations in the gene endothelin receptor B (EDNRB), which is involved in Hirschsprung disease, could also predispose individuals to malignant melanoma. They sequenced the gene in 137 patients with malignant melanoma and 130 matched control subjects.

    EDNRB mutations were identified in four control subjects and in 15 patients, 14 of whom carried mutations reported in Hirschsprung disease and/or resulted in loss of gene function. The authors found a direct association between melanoma risk and the presence of EDNRB mutations. They conclude that their data strongly suggest that EDNRB is involved in the predisposition of two different multigenic disorders, Hirschsprung disease and melanoma.

    Contact: Nadem Soufir, Hopital Bichat-Claude Bernard, nadem.soufir@bch.ap-hop-paris.fr

    Treatment
    '"/>



  • Contact: Sarah L. Zielinski
    jncimedia@oxfordjournals.org
    301-841-1287
    Journal of the National Cancer Institute
    6-Sep-2005


    Page: 1 2 3 4

    Related biology news :

    1. Other highlights in the Aug. 7 JNCI
    2. Other highlights in the July 24 JNCI
    3. Other highlights from the July 10 JNCI
    4. Other highlights in JNCI, June 26
    5. Other highlights in JNCI, June 12
    6. Other highlights from the June 6 JNCI
    7. Other highlights in the May 16 JNCI
    8. Other highlights from the April 18 Journal of the National Cancer Institute
    9. Other highlights from the March 21 JNCI
    10. Other highlights in the March 7 JNCI
    11. Other highlights in the Feb. 21 JNCI

    Post Your Comments:
    *Name:
    *Comment:
    *Email:


    (Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
    (Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
    (Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
    Breaking Biology News(10 mins):
    (Date:4/20/2017)... (PRWEB) , ... April 20, 2017 , ... ... Event , this new webinar will explore challenging patient cases when screening for ... the hospital, there may be a need for bridging parental anticoagulation especially for ...
    (Date:4/20/2017)... BARBARA, CALIFORNIA (PRWEB) , ... April 20, 2017 , ... ... optimization firm for the life sciences and healthcare industries, is pleased to announce ... the new established USDM subsidiary “USDM Europe GmbH” based in Germany. , Braemer ...
    (Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
    (Date:4/20/2017)... ... April 20, 2017 , ... Open Therapeutics ... property (IP) sharing and commercialization model. , The Center for Advancing Innovation helps ... of this effort is bringing the IP to the attention of the entrepreneurial ...
    Breaking Biology Technology:
    Cached News: